Acasti Pharma Inc. Contracts & Agreements
33 Contracts & Agreements
- Business Finance (18 contracts)
- Business Operations (4)
- Human Resources (5)
- Mergers & Acquisitions (1)
- Uncategorized (5)
- Form of Common Stock Certificate (Filed With SEC on October 7, 2024)
- Acasti Pharma Inc. 2024 Equity Incentive Plan (Filed With SEC on September 30, 2024)
- Letter Agreement by and between Prashant Kohli and the Company, dated August 12, 2024 (Filed With SEC on August 16, 2024)
- Form of 2024 NSO Stock Option Award Agreement (Filed With SEC on June 27, 2024)
- Form of 2024 ISO Stock Option Award Agreement (Filed With SEC on June 27, 2024)
- Form of Delaware Director and Officer Indemnification Agreement (Filed With SEC on June 27, 2024)
- Offer Letter by and between Robert J. DelAversano and the Company, dated November 21, 2023 (Filed With SEC on January 8, 2024)
- Settlement Agreement, dated October 18, 2023, by and between the Company and Aker BioMarine Antarctic AS (Filed With SEC on October 23, 2023)
- Form of Securities Purchase Agreement, dated September 24, 2023, by and between the Company and each of the Purchasers signatory thereto (Filed With SEC on September 26, 2023)
- Form of Pre-Funded Warrant, dated September 25, 2023 (Filed With SEC on September 26, 2023)
- Form of Common Warrant, dated September 25, 2023 (Filed With SEC on September 26, 2023)
- Form of Stock Option Agreement for Non-Employee Directors under the Acasti Pharma Stock Option Plan (Filed With SEC on August 11, 2023)
- Form of Stock Option Agreement for Employees under the Acasti Pharma Inc. Stock Option Plan (Filed With SEC on August 11, 2023)
- Employment Agreement with Brian Ford dated September 23, 2021 (Filed With SEC on June 21, 2022)
- Acasti Pharma Inc., Stock Option Plan, as amended June 24, 2021 (Filed With SEC on June 21, 2022)
- Description of Securities (Filed With SEC on June 21, 2022)
- Form of Grace Therapeutics Inc. First Amendment to the Stockholders Agreement (Filed With SEC on July 1, 2021)
- Form of Grace Therapeutics Inc. Stockholders Agreement (Filed With SEC on July 1, 2021)
- Form of Second Amendment to 2018 Convertible Note Purchase Agreements and Amendment to Convertible Promissory Notes (Filed With SEC on July 1, 2021)
- Form of Amendment to 2018 Convertible Note Purchase Agreements (Filed With SEC on July 1, 2021)
- Form of Amendment to 2017 Convertible Note Purchase Agreement and Amended and Restated Convertible Promissory Notes (Filed With SEC on July 1, 2021)
- Form of 2017 Convertible Note Purchase Agreement (Filed With SEC on July 1, 2021)
- Form of 2018 Convertible Note Purchase Agreement (Filed With SEC on July 1, 2021)
- Form of 2017 Amended and Restated Convertible Promissory Note (Filed With SEC on July 1, 2021)
- Form of 2017 Convertible Promissory Note (Filed With SEC on July 1, 2021)
- Form of 2018 Convertible Promissory Note (Filed With SEC on July 1, 2021)
- Independent contractor agreement with PFC Business Advisory Services Inc. dated September 14, 2020, and amended March 15, 2021, and June 16, 2021 (Filed With SEC on June 22, 2021)
- Acasti Pharma Inc., Stock Option Plan, as amended August 27, 2020 (Filed With SEC on June 22, 2021)
- Acasti Pharma Inc., Equity Incentive Plan, as amended August 27, 2020 (Filed With SEC on June 22, 2021)
- Form of Voting Agreement by and between Acasti and each of the Specified Grace Stockholders (Filed With SEC on May 7, 2021)
- Agreement and Plan of Merger, dated as of May 7, 2021, by and among Acasti, Grace and MergerCo (Filed With SEC on May 7, 2021)
- Retention agreement, dated October 27, 2020, between Acasti Pharma Inc. and Jan DAlvise (Filed With SEC on November 16, 2020)
- Retention agreement, dated October 29, 2020 between Acasti Pharma Inc. and Pierre Lemieux (Filed With SEC on November 16, 2020)
